Impact of dipeptidyl peptidase-4 inhibitors on incidence of colorectal cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
Authors:
Open Access
- 1 January 2025
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 16
Abstract
Background: The association between dipeptidyl peptidase-4 inhibitors (DPP-4i) exposure and the risk of colorectal cancer (CRC) in patients with type 2 diabetes mellitus (T2DM) is unclear. Objectives: This meta-analysis aims to investigate the relationship between DPP-4i exposure and the incidence of CRC in patients with T2DM. Design: A systematic review and meta-analysis. Methods: A comprehensive search of electronic databases, including PubMed, Web of Science, EMBASE, and ScienceDirect, was conducted up to March 2024. The studies including randomized clinical trials (RCTs), cohort studies, and case–control studies were retrieved. The odds ratio (OR) was calculated using Stata 12.0 statistical software. The primary outcome assessed was the incidence of CRC. Results: This meta-analysis incorporated six retrospective cohort studies and two case–control studies. The findings indicate that the incidence of CRC in the DPP-4i exposure group was significantly higher than that in the control group (OR = 1.11, 95% CI: 1.02–1.21, p = 0.013). Subgroup analysis revealed that both male (OR = 2.07, p < 0.001) and female participants (OR = 1.49, p = 0.05) in the DPP-4i exposure group exhibited a significantly higher incidence of CRC compared to the control group. Among participants younger than 65 years, the incidence of CRC was markedly elevated in the exposure group (OR = 2.81, p < 0.001). Furthermore, when the exposure duration was less than 1 year, the CRC incidence in the exposure group surpassed that of the control group (OR = 1.24, p = 0.005). When sulfonylureas (SU) were used as control drugs, the incidence of CRC was higher in the exposure group (OR = 1.10, p = 0.017). Conclusion: There is a potential correlation between DPP-4i exposure and increased incidence of CRC in T2DM patients. This association appears to be influenced by gender, age, duration of exposure, and the choice of control medications. Therefore, attention should be paid to colorectal diseases when DPP-4i is employed in the clinic. Trial registration: The meta-analysis has been registered with the International Prospective Register of Systematic Reviews (PROSPERO). The registration number is CRD42024535292.Keywords
This publication has 34 references indexed in Scilit:
- Diabetes in older people: new insights and remaining challengesThe Lancet Diabetes & Endocrinology, 2015
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care, 2014
- Colorectal cancerThe Lancet, 2014
- Gliclazide may have an antiapoptotic effect related to its antioxidant properties in human normal and cancer cellsMolecular Biology Reports, 2011
- Inhibition of multifunctional dipeptidyl peptidase-IV: Is there a risk of oncological and immunological adverse effects?Diabetes Research and Clinical Practice, 2010
- The dipeptidyl peptidase IV family in cancer and cell biologyThe FEBS Journal, 2010
- DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cellsRegulatory Peptides, 2006
- Interplay of Insulin-Like Growth Factor-II, Insulin-Like Growth Factor-I, Insulin-Like Growth Factor-I Receptor, COX-2, and Matrix Metalloproteinase-7, Play Key Roles in the Early Stage of Colorectal CarcinogenesisClinical Cancer Research, 2004
- Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in miceGut, 2004
- Characterization of the synergistic effect of insulin and transferrin and the regulation of their receptors on a human colon carcinoma cell lineInternational Journal of Cancer, 1990